Being a FIPCO—a fully integrated pharmaceutical company—is so last century. Increasingly, many pharmas are adopting strategies that rely heavily on collaborations with multiple partners where those allies bear a much greater proportion of the development risk in exchange for a greater share of the economic reward. In the twenty-first century parlance, it’s about FIPNets—fully integrated pharmaceutical networks.
Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality...
